Impact of Biologic Therapy on Emergency Department Utilization in Pediatric Hidradenitis Suppurativa Patients

Kenan Kherallah, Claire S. Chung, Meagan Hughes, Vivian Y. Shi, Jennifer L. Hsiao, Katrina H. Lee
Pediatric Dermatology · Wiley · 2026-10-08 · DOI: 10.1111/pde.70364

Аннотация

ABSTRACT Hidradenitis suppurativa (HS) is a chronic inflammatory condition that often begins in adolescence and is associated with substantial morbidity and increased healthcare utilization, including emergency department (ED) visits. Using the TriNetX Global Network, a retrospective cohort study was conducted comparing pediatric HS patients who received biologic therapy before adulthood with biologic‐naïve pediatric HS controls. Biologic exposure was associated with a lower cumulative incidence of 1 or more all‐cause ED visits at 5 years (RR: 0.75, 95% CI: 0.58–0.97; p = 0.0250), 10 years (RR: 0.65, 95% CI: 0.51–0.84; p = 0.0002), and at any time after index (RR: 0.61, 95% CI: 0.48–0.77; p < 0.0001; NNT, 10). These findings suggest that biologic exposure during pediatric years is associated with lower subsequent all‐cause ED utilization among patients with HS.

Читать у издателя →

Похожие статьи